((WB),1)
(dynamic,2)
((ET),1)
(its,5)
(isolated,1)
(cosmesis 
Using,1)
(respectively 
CEST,1)
(maintained,1)
(added,2)
(bisphosphonate,3)
(received,7)
(type,3)
(polyploid;,1)
(through,3)
(13 5%,1)
((ESI),1)
(receptors-ERα36,1)
(fever,,1)
(aronia,1)
(studies 
Meta-analysis,1)
(great,1)
(spite,1)
(implementation,1)
(studies 
,1)
(substantially,2)
(these,3)
(tissues,4)
((study,2)
(research,2)
(inhibitor,4)
(paradigm,1)
(camphorata,1)
(includes,1)
(applied,1)
(penetration,2)
(polymerase,2)
(1 
There,1)
(adipose,2)
(downregulated,4)
(sustained,1)
(mice,2)
(Twist 
In,1)
((50 6%),,2)
(wild-type,1)
(18,1)
(recurrent,1)
(Circular,1)
(superoxide,2)
((32 1%),1)
(our,5)
(transfected,1)
(generated,1)
(signaling,6)
(Interleukin-1�,1)
(mortality 
The,1)
(blotting,1)
(lines 
The,3)
(participated,1)
(study,,3)
(optimizing,1)
(progression-free,1)
(Japanese,2)
(self-reports,1)
(G1,2)
(review,,2)
(addition,1)
(immunotherapy,,1)
((91 2%),1)
(during,2)
(fractions,,1)
(array,2)
(stem,1)
(offsets,1)
(CI:,5)
(photographs 
Nineteen,1)
(regulates,1)
(appointment 
It,1)
((AI),1)
(favorable,1)
(associated,8)
(significance,2)
(improvements,2)
(appointment 
Productive,1)
(treatments,2)
(2 years,1)
(localized,1)
(differentiate,1)
(S961 
S961,1)
(p = 0 006),1)
(at,18)
((bacteriophages),1)
(429,1)
(EgKI-1,3)
(voxel,2)
(3-O-p-coumaroyltormentic,2)
((DPPH),1)
(tissue 
Together,1)
(boost ,1)
(progression 
In,1)
(sampling,3)
(outcomes 
However,,1)
(laboratory,1)
(39,1)
(ET,1)
(amplitude,,1)
(whereas,2)
(due,4)
(cases,,2)
(AI,2)
(safety,1)
(partially,1)
(probably,1)
(sexuality,1)
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium,1)
(4,,1)
(or,14)
(improves,1)
(treatment 
Presently,,1)
(gemcitabine(GEM),,1)
(pathway-related,2)
(aromatase,3)
(5 ,1)
(tools,2)
(activation,,1)
(suspicious,1)
(scanned,1)
(VMAT-SIB,2)
(anticipated,1)
(ERα66,,1)
(often,1)
(technique,3)
(reliable 
Its,1)
(functions,1)
(inhibits,2)
((44 6%) 
Two-thirds,1)
(compound 
Using,1)
(led,3)
(formulation,1)
(breast 
This,1)
(retrospective,1)
(regions ,1)
(results,12)
(exhibits,1)
(2010,1)
(morphology,1)
(describe,1)
(doses(Level,1)
(early-stage,1)
(changed,1)
(helps,1)
(nine,1)
(inconsistent 
Although,1)
(ppm,2)
(mRNA,,1)
(1) 
Seven,1)
(range,1)
(association,7)
(therapeutic 
,1)
(although,1)
(1 40,,1)
(needed,1)
(consecutive,1)
(growth 
Furthermore,,1)
(second-leading,2)
(﻿The,2)
(24,1)
(centers,1)
(T47D,,1)
(estradiol,1)
(2012 
Data,1)
(reported,1)
(burden 
Bioinformatic,1)
(binds,1)
(settings,1)
(SSM,1)
(0 002),1)
(evaluate,2)
(cancers,1)
(ratios,1)
(liver,1)
(bromide,2)
(damage,1)
(August,1)
(95%,6)
(follow-up 
A,1)
(predictive,3)
(by,39)
(mean,2)
(signals,1)
(regulating,3)
((MBC),1)
(setting 
We,1)
(57 5,,1)
(confirmed,4)
(review,5)
(therapy 
History,1)
((ZJU-0327,1)
(phenotype,,1)
(implication,1)
(whole,1)
(number,1)
(6,1)
(higher,7)
(with,81)
(January,1)
(preventive,1)
(comparable,1)
(species,1)
(1 year,1)
(reduced,2)
((late,1)
(inhibited,5)
(expression,20)
(consistently,1)
((CEST),1)
(promote,1)
(apoptosis-related,1)
(S961,4)
(impaired,1)
(cells,18)
(understanding,1)
(organs 
Larval,1)
(creation,1)
(females,3)
(plant,1)
(lines,,2)
(hormonal-therapy,1)
(dependent,2)
(Triple-negative,1)
(nature,1)
(hydroxyl,2)
(pain,,1)
(hypofractionation,1)
(females,,1)
(their,5)
(longitudinally 
We,1)
(urinary,1)
(match,1)
(xenograft,2)
((ER)-positive,2)
(0 001) 
Sexual,1)
(iodide,1)
((CDK),1)
(IRs,3)
(choice,1)
(engendering,1)
(years,,3)
(activity,5)
(residual,1)
(normal,4)
(motif,1)
(distinction,1)
(hold,1)
(ER-driven 
Long-term,1)
(Intensive,1)
(ESR1 
Subgroup,1)
(five-year,1)
(GSK3β 
Notably,,1)
